{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:54:27Z","timestamp":1793858067626,"version":"4.6.1"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Ministerio de Asuntos Econ\u00f3micos y Transformaci\u00f3n Digital, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["PI13\/01529"],"award-info":[{"award-number":["PI13\/01529"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["IT616\/13"],"award-info":[{"award-number":["IT616\/13"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2015-67457-R"],"award-info":[{"award-number":["SAF2015-67457-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006365","name":"Universidad de Cantabria","doi-asserted-by":"publisher","award":["747487"],"award-info":[{"award-number":["747487"]}],"id":[{"id":"10.13039\/501100006365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006365","name":"Universidad de Cantabria","doi-asserted-by":"publisher","award":["H2020-MSCA-IF-2016"],"award-info":[{"award-number":["H2020-MSCA-IF-2016"]}],"id":[{"id":"10.13039\/501100006365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bcp.2018.07.009","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T15:12:21Z","timestamp":1531840341000},"page":"97-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["The endocannabinoid system in mental disorders: Evidence from human brain studies"],"prefix":"10.1016","volume":"157","author":[{"given":"In\u00e9s","family":"Ibarra-Lecue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuencisla","family":"Pilar-Cu\u00e9llar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Muguruza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Florensa-Zanuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Urig\u00fcen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Pazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Callado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9904","key":"10.1016\/j.bcp.2018.07.009_b0005","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2018.07.009_b0010","first-page":"3","article-title":"Do post-mortem brain studies provide useful information for Psychiatry?","volume":"7","author":"Meana","year":"2014","journal-title":"Rev. Psiquiatr. Salud Ment (Barc.)"},{"issue":"4","key":"10.1016\/j.bcp.2018.07.009_b0015","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0447.2011.01687.x","article-title":"Endocannabinoid system dysfunction in mood and related disorders","volume":"124","author":"Ashton","year":"2011","journal-title":"Acta Psychiatr. Scand."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2018.07.009_b0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00008877-200509000-00006","article-title":"Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?","volume":"16","author":"Hill","year":"2005","journal-title":"Behav. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.009_b0025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.euroneuro.2005.03.003","article-title":"Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test","volume":"15","author":"Hill","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.expneurol.2010.03.018","article-title":"The endocannabinoid system and psychiatric disorders","volume":"224","author":"Parolaro","year":"2010","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pnpbp.2012.01.008","article-title":"Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders","volume":"38","author":"Carvalho","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2018.07.009_b0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu. Rev. Psychol."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0045","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.bcp.2018.07.009_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International union of pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/157015907780866884","article-title":"The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration","volume":"5","author":"Ashton","year":"2007","journal-title":"Curr. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pbb.2005.01.029","article-title":"Endocannabinoid system and stress and anxiety responses","volume":"81","author":"Viveros","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bcp.2018.07.009_b0070","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neuroscience.2011.11.057","article-title":"Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it","volume":"204","author":"Riebe","year":"2012","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/0269881111408958","article-title":"The endocannabinoid system in anxiety, fear memory and habituation","volume":"26","author":"Ruehle","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2018.07.009_b0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fnbeh.2011.00034","article-title":"The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus","volume":"5","author":"Akirav","year":"2011","journal-title":"Front. Behav. Neurosci."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0085","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/mp.2012.72","article-title":"Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity","volume":"18","author":"Gunduz-Cinar","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2018.07.009_b0090","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.53","article-title":"Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation","volume":"4","author":"Bluett","year":"2014","journal-title":"Transl. Psychiatry"},{"issue":"9","key":"10.1016\/j.bcp.2018.07.009_b0095","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1523\/JNEUROSCI.2737-14.2015","article-title":"Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety","volume":"35","author":"Gray","year":"2015","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","article-title":"Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study","volume":"11","author":"Herkenham","year":"1991","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuropharm.2007.06.024","article-title":"CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour","volume":"54","author":"Rubino","year":"2008","journal-title":"Neuropharmacology"},{"issue":"45","key":"10.1016\/j.bcp.2018.07.009_b0110","doi-asserted-by":"crossref","first-page":"14980","DOI":"10.1523\/JNEUROSCI.4283-10.2010","article-title":"Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output","volume":"30","author":"Hill","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2018.07.009_b0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neuroscience.2011.12.030","article-title":"Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis","volume":"204","author":"Hill","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2018.07.009_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neuroscience.2011.10.006","article-title":"Timing is everything: evidence for a role of corticolimbic endocannabinoids in modulating hypothalamic-pituitary-adrenal axis activity across developmental periods","volume":"204","author":"Lee","year":"2012","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/npp.2015.166","article-title":"Neurobiological interactions between stress and the endocannabinoid system","volume":"41","author":"Morena","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.euroneuro.2010.06.007","article-title":"Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype","volume":"21","author":"Aso","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0135","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.neuropharm.2004.01.003","article-title":"Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors","volume":"46","author":"Uriguen","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.07.009_b0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neuroscience.2011.09.031","article-title":"CB1 receptor-deficient mice as a model for depression","volume":"204","author":"Valverde","year":"2012","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.bcp.2018.07.009_b0145","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.npp.1300601","article-title":"Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress","volume":"30","author":"Hill","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.bcp.2018.07.009_b0150","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2006.12.001","article-title":"Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress","volume":"62","author":"Bortolato","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.bcp.2018.07.009_b0155","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/mp.2012.90","article-title":"Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure","volume":"18","author":"Hill","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0160","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/npp.2014.198","article-title":"Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain","volume":"40","author":"Lomazzo","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2018.07.009_b0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0074-7742(09)85005-8","article-title":"The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs","volume":"85","author":"Gaetani","year":"2009","journal-title":"Int. Rev. Neurobiol."},{"issue":"9","key":"10.1016\/j.bcp.2018.07.009_b0170","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2009.06.006","article-title":"The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants","volume":"30","author":"Hill","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.009_b0175","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/JCP.0000000000000581","article-title":"Targeting the endocannabinoid system in psychiatric illness","volume":"36","author":"Katzman","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0180","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/0269881111408459","article-title":"The endocannabinoid system in the regulation of emotions throughout lifespan: a discussion on therapeutic perspectives","volume":"26","author":"Marco","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"Pt A","key":"10.1016\/j.bcp.2018.07.009_b0185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neubiorev.2016.12.033","article-title":"The endocannabinoid system as a target for novel anxiolytic drugs","volume":"76","author":"Patel","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bcp.2018.07.009_b0190","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-319-20825-1_9","article-title":"Endocannabinoids and mental disorders","volume":"231","author":"Rubino","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2018.07.009_b0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4088\/JCP.11096su1c.01","article-title":"The epidemiology of depression and the evolution of treatment","volume":"73","author":"Hirschfeld","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.bcp.2018.07.009_b0200","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1359-6446(05)03398-2","article-title":"Strategies for producing faster acting antidepressants","volume":"10","author":"Adell","year":"2005","journal-title":"Drug Discov. Today"},{"issue":"23","key":"10.1016\/j.bcp.2018.07.009_b0205","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.2174\/13816128113196660734","article-title":"Serotonin 5-HT4 receptors: a new strategy for developing fast acting antidepressants?","volume":"20","author":"Vidal","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"11","key":"10.1016\/j.bcp.2018.07.009_b0210","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1360-0443.2003.00437.x","article-title":"Exploring the association between cannabis use and depression","volume":"98","author":"Degenhardt","year":"2003","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.bcp.2018.07.009_b0215","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1017\/S0033291713001438","article-title":"The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies","volume":"44","author":"Lev-Ran","year":"2014","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1943-278X.1999.tb00761.x","article-title":"Personality traits and cognitive styles as risk factors for serious suicide attempts among young people","volume":"29","author":"Beautrais","year":"1999","journal-title":"Suicide Life Threat. Behav."},{"issue":"5","key":"10.1016\/j.bcp.2018.07.009_b0225","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1365-2125.1981.tb01294.x","article-title":"The seed and the soil: effect of dosage, personality and starting state on the response to delta 9 tetrahydrocannabinol in man","volume":"12","author":"Ashton","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.009_b0230","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.addbeh.2005.05.052","article-title":"Decreased depression in marijuana users","volume":"31","author":"Denson","year":"2006","journal-title":"Addict. Behav."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0235","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1522-7162(1996)4:2<77::AID-DEPR7>3.0.CO;2-C","article-title":"Do patients use marijuana as an antidepressant?","volume":"4","author":"Gruber","year":"1996","journal-title":"Depression"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0240","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00126334-200401010-00005","article-title":"Patterns of marijuana use among patients with HIV\/AIDS followed in a public health care setting","volume":"35","author":"Prentiss","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.009_b0245","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/archpsyc.1973.01750330041007","article-title":"9 -Tetrahydrocannabinol in depressed patients","volume":"28","author":"Kotin","year":"1973","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.bcp.2018.07.009_b0250","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1192\/bjp.bp.109.065227","article-title":"Cannabis and suicide: longitudinal study","volume":"195","author":"Price","year":"2009","journal-title":"Br. J. Psychiatry"},{"issue":"5\u20136","key":"10.1016\/j.bcp.2018.07.009_b0255","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00008877-200509000-00005","article-title":"A role for cannabinoid CB1 receptors in mood and anxiety disorders","volume":"16","author":"Witkin","year":"2005","journal-title":"Behav. Pharmacol."},{"issue":"9600","key":"10.1016\/j.bcp.2018.07.009_b0260","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.bcp.2018.07.009_b0265","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","article-title":"Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"issue":"43","key":"10.1016\/j.bcp.2018.07.009_b0270","doi-asserted-by":"crossref","first-page":"11700","DOI":"10.1523\/JNEUROSCI.1636-07.2007","article-title":"Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex","volume":"27","author":"Bambico","year":"2007","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.009_b0275","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.biopsych.2004.10.032","article-title":"Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents","volume":"57","author":"Griebel","year":"2005","journal-title":"Biol. Psychiatry"},{"issue":"5\u20136","key":"10.1016\/j.bcp.2018.07.009_b0280","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/FBP.0b013e3282ee7b44","article-title":"Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect","volume":"18","author":"McLaughlin","year":"2007","journal-title":"Behav. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2018.07.009_b0285","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.physbeh.2009.04.023","article-title":"Protracted cannabinoid administration elicits antidepressant behavioral responses in rats: role of gender and noradrenergic transmission","volume":"98","author":"Morrish","year":"2009","journal-title":"Physiol. Behav."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0290","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2007.09.008","article-title":"Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice","volume":"33","author":"Steiner","year":"2008","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0295","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/14728222.10.2.203","article-title":"Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders","volume":"10","author":"Vinod","year":"2006","journal-title":"Expert Opin. Ther. Targets"},{"issue":"6 Pt B","key":"10.1016\/j.bcp.2018.07.009_b0300","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1006\/nbdi.1998.0224","article-title":"Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion","volume":"5","author":"Murphy","year":"1998","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.009_b0305","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/0091-3057(86)90515-0","article-title":"Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects","volume":"24","author":"Cone","year":"1986","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1\u20136","key":"10.1016\/j.bcp.2018.07.009_b0310","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0022-4731(89)90090-3","article-title":"The effects of 9-ene-tetrahydrocannabinol on hormone release and immune function","volume":"34","author":"Dax","year":"1989","journal-title":"J. Steroid Biochem."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.009_b0315","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00213-008-1422-2","article-title":"The effects of cannabinoids on serum cortisol and prolactin in humans","volume":"203","author":"Ranganathan","year":"2009","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.bcp.2018.07.009_b0320","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1177\/0269881112446530","article-title":"Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images","volume":"26","author":"Ballard","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2018.07.009_b0325","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.euroneuro.2013.06.009","article-title":"The endocannabinoid system and emotional processing: a pharmacological fMRI study with 9-tetrahydrocannabinol","volume":"23","author":"Bossong","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.009_b0330","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1469-7610.2007.01728.x","article-title":"Depressive symptoms in adolescents: associations with white matter volume and marijuana use","volume":"48","author":"Medina","year":"2007","journal-title":"J. Child Psychol. Psychiatry"},{"key":"10.1016\/j.bcp.2018.07.009_b0335","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nicl.2015.03.024","article-title":"Poorer frontolimbic white matter integrity is associated with chronic cannabis use, FAAH genotype, and increased depressive and apathy symptoms in adolescents and young adults","volume":"8","author":"Shollenbarger","year":"2015","journal-title":"Neuroimage Clin."},{"issue":"22","key":"10.1016\/j.bcp.2018.07.009_b0340","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1523\/JNEUROSCI.22-22-09742.2002","article-title":"Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase\/Akt signaling","volume":"22","author":"Molina-Holgado","year":"2002","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0345","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.pnpbp.2010.11.021","article-title":"Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants","volume":"35","author":"Gorzalka","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0350","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/sj.mp.4001376","article-title":"Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims","volume":"9","author":"Hungund","year":"2004","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0355","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jpsychires.2012.03.021","article-title":"Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear","volume":"46","author":"Choi","year":"2012","journal-title":"J. Psychiatr. Res."},{"issue":"10","key":"10.1016\/j.bcp.2018.07.009_b0360","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/npp.2010.75","article-title":"Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder","volume":"35","author":"Eggan","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.bcp.2018.07.009_b0365","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00702-007-0660-5","article-title":"Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression","volume":"114","author":"Koethe","year":"2007","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"12","key":"10.1016\/j.bcp.2018.07.009_b0370","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00702-008-0131-7","article-title":"Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents","volume":"115","author":"Hill","year":"2008","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"8","key":"10.1016\/j.bcp.2018.07.009_b0375","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/npp.2009.19","article-title":"CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms","volume":"34","author":"Juhasz","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2018.07.009_b0380","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00213-013-2995-y","article-title":"Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment","volume":"227","author":"Mitjans","year":"2013","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0385","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.tpj.6500301","article-title":"Depression in Parkinson\u2019s disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)","volume":"5","author":"Barrero","year":"2005","journal-title":"Pharmacogenomics J."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0390","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/ajad.12273","article-title":"A cannabinoid receptor 1 polymorphism is protective against major depressive disorder in methadone-maintained outpatients","volume":"24","author":"Icick","year":"2015","journal-title":"Am. J. Addict."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0395","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/archgenpsychiatry.2011.2273","article-title":"Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression","volume":"69","author":"Agrawal","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.bcp.2018.07.009_b0400","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.euroneuro.2008.05.003","article-title":"Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression","volume":"18","author":"Domschke","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001640","article-title":"Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects","volume":"3","author":"Onaivi","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0410","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/syn.20714","article-title":"A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands","volume":"64","author":"Ishiguro","year":"2010","journal-title":"Synapse"},{"issue":"10","key":"10.1016\/j.bcp.2018.07.009_b0415","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.biopsych.2009.09.024","article-title":"Brain cannabinoid CB2 receptor in schizophrenia","volume":"67","author":"Ishiguro","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.bcp.2018.07.009_b0420","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/FPC.0b013e3283367c6b","article-title":"Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor","volume":"20","author":"Carrasquer","year":"2010","journal-title":"Pharmacogenet. Genomics"},{"issue":"10","key":"10.1016\/j.bcp.2018.07.009_b0425","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1177\/0269881112454229","article-title":"Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes","volume":"26","author":"Mitjans","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2018.07.009_b0430","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41398-017-0029-y","article-title":"Schizophrenia and depression, two poles of endocannabinoid system deregulation","volume":"7","author":"Rodriguez-Munoz","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"5","key":"10.1016\/j.bcp.2018.07.009_b0435","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.phrs.2010.01.002","article-title":"Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression","volume":"61","author":"Monteleone","year":"2010","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.009_b0440","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.euroneuro.2016.03.003","article-title":"Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma","volume":"26","author":"Lazary","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0445","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-2007-993211","article-title":"Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report","volume":"41","author":"Hill","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"10.1016\/j.bcp.2018.07.009_b0450","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.psyneuen.2009.03.013","article-title":"Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress","volume":"34","author":"Hill","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bcp.2018.07.009_b0455","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1476-511X-11-32","article-title":"Serum contents of endocannabinoids are correlated with blood pressure in depressed women","volume":"11","author":"Ho","year":"2012","journal-title":"Lipids Health Dis."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.009_b0460","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.psyneuen.2011.09.017","article-title":"Intense exercise increases circulating endocannabinoid and BDNF levels in humans\u2013possible implications for reward and depression","volume":"37","author":"Heyman","year":"2012","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"10.1016\/j.bcp.2018.07.009_b0465","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/ajmg.b.30693","article-title":"Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder","volume":"147B","author":"Lu","year":"2008","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"8","key":"10.1016\/j.bcp.2018.07.009_b0470","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/ajmg.b.31024","article-title":"Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype","volume":"150B","author":"Lazary","year":"2009","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.bcp.2018.07.009_b0475","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fnbeh.2015.00235","article-title":"Cannabinoid type-1 receptor signaling in central serotonergic neurons regulates anxiety-like behavior and sociability","volume":"9","author":"Haring","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.bcp.2018.07.009_b0480","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lfs.2017.11.029","article-title":"Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects","volume":"192","author":"Mendiguren","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2018.07.009_b0485","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.90","article-title":"Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1","volume":"2","author":"Heitland","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0490","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/npp.2017.143","article-title":"The role of the endocannabinoid system and genetic variation in adolescent brain development","volume":"43","author":"Meyer","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0495","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.b.32467","article-title":"Genetic variation in the endocannabinoid system and response to Cognitive Behavior Therapy for child anxiety disorders","volume":"174","author":"Lester","year":"2017","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"9","key":"10.1016\/j.bcp.2018.07.009_b0500","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/mp.2013.61","article-title":"Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study","volume":"18","author":"Neumeister","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.bcp.2018.07.009_b0505","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1038\/npp.2014.110","article-title":"Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors","volume":"39","author":"Pietrzak","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0510","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41398-018-0141-7","article-title":"Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors","volume":"8","author":"Bedse","year":"2018","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0515","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biopsych.2008.10.047","article-title":"Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function","volume":"66","author":"Hariri","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.bcp.2018.07.009_b0520","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.tips.2013.08.008","article-title":"Amygdala FAAH and anandamide: mediating protection and recovery from stress","volume":"34","author":"Gunduz-Cinar","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2018.07.009_b0525","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1038\/ncomms7395","article-title":"FAAH genetic variation enhances fronto-amygdala function in mouse and human","volume":"6","author":"Dincheva","year":"2015","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bcp.2018.07.009_b0530","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/jcbfm.2015.119","article-title":"The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB","volume":"35","author":"Boileau","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bcp.2018.07.009_b0535","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.1","article-title":"Fatty-acid amide hydrolase polymorphisms and post-traumatic stress disorder after penetrating brain injury","volume":"2","author":"Pardini","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0540","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1517\/17460441.2014.966680","article-title":"Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease","volume":"10","author":"Wyrofsky","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.009_b0545","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40263-013-0051-4","article-title":"Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment","volume":"27","author":"Bailey","year":"2013","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2018.07.009_b0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062741","article-title":"Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder","volume":"8","author":"Hauer","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bcp.2018.07.009_b0555","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/npp.2012.100","article-title":"Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans","volume":"37","author":"Dlugos","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.bcp.2018.07.009_b0560","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.psyneuen.2013.08.004","article-title":"Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks","volume":"38","author":"Hill","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bcp.2018.07.009_b0565","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pnpbp.2016.01.004","article-title":"Reductions in circulating endocannabinoid 2-arachidonoylglycerol levels in healthy human subjects exposed to chronic stressors","volume":"67","author":"Yi","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.bcp.2018.07.009_b0570","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.biopsych.2015.12.021","article-title":"Interactions between anandamide and corticotropin-releasing factor signaling modulate human amygdala function and risk for anxiety disorders: an imaging genetics strategy for modeling molecular interactions","volume":"80","author":"Demers","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2018.07.009_b0575","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.psyneuen.2018.03.009","article-title":"Circulating endocannabinoids and affect regulation in human subjects","volume":"92","author":"Coccaro","year":"2018","journal-title":"Psychoneuroendocrinology"},{"issue":"10100","key":"10.1016\/j.bcp.2018.07.009_b0580","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Abajobir","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bcp.2018.07.009_b0585","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0166-2236(98)01283-1","article-title":"Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action","volume":"21","author":"Di Marzo","year":"1998","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bcp.2018.07.009_b0590","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-neuro-062111-150420","article-title":"Multiple functions of endocannabinoid signaling in the brain","volume":"35","author":"Katona","year":"2012","journal-title":"Annu. Rev. Neurosci."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0595","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1586\/14737175.8.7.1037","article-title":"Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia","volume":"8","author":"Muller-Vahl","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.bcp.2018.07.009_b0600","series-title":"Du hachisch et de l\u2019ali\u00e9nation mentale: \u00e9tudes psycholo-giques","author":"Moreau","year":"1845"},{"issue":"4","key":"10.1016\/j.bcp.2018.07.009_b0605","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.neuroimage.2010.04.034","article-title":"Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR","volume":"52","author":"Wong","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.bcp.2018.07.009_b0610","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","article-title":"Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia","volume":"79","author":"Ceccarini","year":"2013","journal-title":"Neuroimage"},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0615","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biopsych.2016.02.007","article-title":"Marijuana and madness: associations between cannabinoids and psychosis","volume":"79","author":"Ranganathan","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.bcp.2018.07.009_b0620","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.biopsych.2016.04.015","article-title":"Positron emission tomography studies on cannabinoid receptor Type 1 in schizophrenia","volume":"79","author":"Mihov","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0625","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0306-4522(00)00552-2","article-title":"Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use","volume":"103","author":"Dean","year":"2001","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0630","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pnpbp.2003.11.005","article-title":"Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia","volume":"28","author":"Zavitsanou","year":"2004","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.bcp.2018.07.009_b0635","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00221-006-0503-x","article-title":"Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia","volume":"172","author":"Newell","year":"2006","journal-title":"Exp. Brain Res."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.009_b0640","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12264-007-0051-9","article-title":"No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia","volume":"23","author":"Deng","year":"2007","journal-title":"Neurosci. Bull."},{"issue":"8","key":"10.1016\/j.bcp.2018.07.009_b0645","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/npp.2011.43","article-title":"Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex","volume":"36","author":"Dalton","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.bcp.2018.07.009_b0650","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2012.07.021","article-title":"Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia","volume":"141","author":"Jenko","year":"2012","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0655","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.schres.2014.07.017","article-title":"Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia","volume":"159","author":"Volk","year":"2014","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2018.07.009_b0660","first-page":"173","article-title":"Morphology of the lateral superior temporal gyrus in neuroleptic nai;ve patients with schizophrenia: relationship to symptoms","volume":"60","author":"Kim","year":"2003","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0665","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/npp.2009.116","article-title":"Amygdalocortical circuitry in schizophrenia: from circuits to molecules","volume":"35","author":"Benes","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2018.07.009_b0670","doi-asserted-by":"crossref","unstructured":"American, Psychiatric, Association, Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), in: Washington, DC, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0675","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0680","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","article-title":"Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia","volume":"65","author":"Eggan","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0685","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00213-009-1608-2","article-title":"Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment","volume":"206","author":"Uriguen","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2018.07.009_b0690","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-511X-2-5","article-title":"Endocannabinoid signalling in the blood of patients with schizophrenia","volume":"2","author":"De Marchi","year":"2003","journal-title":"Lipids Health Dis."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.009_b0695","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00041444-200010030-00008","article-title":"Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia","volume":"10","author":"Tsai","year":"2000","journal-title":"Psychiatr. Genet."},{"key":"10.1016\/j.bcp.2018.07.009_b0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0920-9964(95)95120-X","article-title":"Identification of a highly polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies of schizophrenia","volume":"15","author":"Dawson","year":"1995","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0705","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.tpj.6500352","article-title":"(AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population","volume":"6","author":"Ballon","year":"2006","journal-title":"Pharmacogenomics J."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0710","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00406-006-0665-3","article-title":"(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population","volume":"256","author":"Martinez-Gras","year":"2006","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0715","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neulet.2007.08.008","article-title":"No association of CNR1 gene variations with susceptibility to schizophrenia","volume":"426","author":"Seifert","year":"2007","journal-title":"Neurosci. Lett."},{"issue":"5","key":"10.1016\/j.bcp.2018.07.009_b0720","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.mp.4001029","article-title":"CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia","volume":"7","author":"Ujike","year":"2002","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.bcp.2018.07.009_b0725","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ajmg.b.30592","article-title":"Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia","volume":"147","author":"Chavarria-Siles","year":"2008","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.bcp.2018.07.009_b0730","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1192\/bjp.bp.107.036129","article-title":"Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use","volume":"191","author":"Zammit","year":"2007","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0735","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2007.05.005","article-title":"The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia","volume":"18","author":"Hamdani","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0740","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/archgenpsychiatry.2010.152","article-title":"Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up","volume":"68","author":"van Winkel","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.bcp.2018.07.009_b0745","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.euroneuro.2012.07.007","article-title":"Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-alpha gene (PPARA) and schizophrenia","volume":"23","author":"Costa","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2018.07.009_b0750","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/YPG.0000000000000047","article-title":"Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population","volume":"24","author":"Bae","year":"2014","journal-title":"Psychiatr. Genet."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.009_b0755","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5455\/bcp.20150502072915","article-title":"Cannabinoid receptor 1 (CNR1) gene polymorphisms in schizophrenia patients: Rs6454674 polymorphism is associated with disease severity","volume":"25","author":"Copoglu","year":"2015","journal-title":"Klinik Psikofarmakoloji B\u00fclteni-Bull. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.009_b0760","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pscychresns.2015.05.005","article-title":"Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms","volume":"233","author":"Suarez-Pinilla","year":"2015","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.009_b0765","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/npp.2009.235","article-title":"A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia","volume":"35","author":"Tiwari","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.bcp.2018.07.009_b0770","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.schres.2011.02.021","article-title":"Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia","volume":"128","author":"Ho","year":"2011","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.bcp.2018.07.009_b0775","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1176\/appi.ajp.2010.10030318","article-title":"Alterations in metabotropic glutamate receptor 1\u03b1 and regulator of G protein signaling 4 in the prefrontal cortex in Schizophrenia","volume":"167","author":"Volk","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.009_b0780","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2013.02.038","article-title":"Endocannabinoid metabolism in the prefrontal cortex in schizophrenia","volume":"147","author":"Volk","year":"2013","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.009_b0785","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neulet.2004.11.050","article-title":"A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia","volume":"376","author":"Morita","year":"2005","journal-title":"Neurosci. Lett."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2018.07.009_b0790","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2013.06.013","article-title":"Quantification of endocannabinoids in postmortem brain of schizophrenic subjects","volume":"148","author":"Muguruza","year":"2013","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.bcp.2018.07.009_b0795","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","article-title":"Elevated endogenous cannabinoids in schizophrenia","volume":"10","author":"Leweke","year":"1999","journal-title":"Neuroreport"},{"issue":"11","key":"10.1016\/j.bcp.2018.07.009_b0800","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.bcp.2018.07.009_b0805","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.009_b0810","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis","volume":"194","author":"Koethe","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.bcp.2018.07.009_b0815","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"6644","key":"10.1016\/j.bcp.2018.07.009_b0820","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/42015","article-title":"A second endogenous cannabinoid that modulates long-term potentiation","volume":"388","author":"Stella","year":"1997","journal-title":"Nature"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218302776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:04:13Z","timestamp":1762095853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218302776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":164,"alternative-id":["S0006295218302776"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.009","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The endocannabinoid system in mental disorders: Evidence from human brain studies","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}